Stephen Pawsey Email

Chief Medical Officer . NeRRe Therapeutics

Current Roles

Employees:
11
Revenue:
$1.7M
About
NeRRe Therapeutics is a clinical stage company progressing a unique portfolio of three neurokinin-1 antagonists (NK-1RAs) for the treatment of common, chronic and debilitating conditions, caused by neuronal hypersensitivity related to NK-1 receptor system dysfunction. It's lead compound orvepitant is in a multinational Phase 2b trial in patients suffering from chronic refractory cough, a neuronal hypersensitivity condition for which there are no approved treatments.
NeRRe Therapeutics Address
Gunnels Wood Rd
Stevenage, null
NeRRe Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.